SG Americas Securities LLC Takes Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

SG Americas Securities LLC bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 17,970 shares of the company's stock, valued at approximately $355,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in KNSA. Braidwell LP increased its stake in shares of Kiniksa Pharmaceuticals by 40.6% during the third quarter. Braidwell LP now owns 2,894,513 shares of the company's stock valued at $72,334,000 after purchasing an additional 836,210 shares in the last quarter. Parkman Healthcare Partners LLC increased its stake in Kiniksa Pharmaceuticals by 16.7% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company's stock valued at $18,874,000 after purchasing an additional 108,102 shares in the last quarter. FMR LLC increased its position in shares of Kiniksa Pharmaceuticals by 36,925.0% during the third quarter. FMR LLC now owns 696,810 shares of the company's stock valued at $17,413,000 after acquiring an additional 694,928 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Kiniksa Pharmaceuticals by 31.2% in the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company's stock worth $12,398,000 after purchasing an additional 157,741 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in shares of Kiniksa Pharmaceuticals by 8.2% during the third quarter. Rice Hall James & Associates LLC now owns 649,630 shares of the company's stock valued at $16,234,000 after buying an additional 49,000 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Insiders Place Their Bets

In other news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the sale, the chief operating officer now directly owns 88,975 shares of the company's stock, valued at approximately $1,622,904. The trade was a 13.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 8,969 shares of the firm's stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now owns 22,958 shares of the company's stock, valued at $492,449.10. This represents a 28.09 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,092 shares of company stock worth $471,609 in the last three months. 54.57% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals Stock Performance

Shares of Kiniksa Pharmaceuticals stock traded down $0.80 during trading hours on Friday, hitting $19.49. The company's stock had a trading volume of 379,450 shares, compared to its average volume of 613,558. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The business has a 50 day moving average price of $20.00 and a two-hundred day moving average price of $23.11. The company has a market cap of $1.41 billion, a PE ratio of -139.20 and a beta of 0.32.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KNSA. Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Monday, January 13th. Evercore ISI boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.